© РИА Томск. Павел Стефанский
TOMSK, Jul 20 – RIA
polytechnics at the TPU Nuclear Research Reactor began the production of
lutetium-177 trichloride, a chemical compound that can later be used for the
manufacture of anticancer drugs, the head of the TPU Laboratory for Isotopic
Analysis and Technologies Igor Shamanin told RIA Tomsk.
Earlier it was reported
that in 2019, for the first time in Russia, at the TPU Nuclear Research Reactor
a trial batch of lutetium-177 isotopes was produced, the synthesis of which is
carried out using a new technology developed in Tomsk. New isotopes were
planned to be used for the treatment of malignant tumors with fewer side
effects than their counterparts.
"We have started the
production of a compound of the isotope lutetium-177 trichloride. It will be
used to synthesize radiopharmaceuticals for the targeted destruction of tumors.
By the end of the year, we will send samples to the Karpov Institute of
Physical Chemistry for an independent examination. There radiochemists will look
at the quality of our lutetium trichloride", – Shamanin said.
© с сайта Томского политехнического университета
According to the agency's
interlocutor, in the fall, a radiopharmaceutical based on the new compound will
be produced at the TPU Nuclear Research Reactor, and its laboratory and
preclinical tests will start in 2021.
University Nuclear Research Reactor – is the only operating university nuclear
reactor in Russia. It was launched in 1967 and has been upgraded several times
since then. The reactor conducts promising research in the field of
environmental management and materials science, nuclear medicine. TPU is one of
the leading Russian centers for the development and production of
radiopharmaceuticals – drugs containing radioisotopes.